Focus on Healthcare (Biotech, Medical Devices & Diagnostics, Digital Health)
Dr. Eric Yu is a Partner of Matrix China. He joined Matrix China in 2014. Dr. Yu‘s investment cases at Matrix China include: Peijia , RemeGen, Chemclin, InventisBio, Biostar, Genecast, Ambrx, Advaccine, Scivita Medcial, etc.
Prior to joining Matrix China, Dr. Yu was responsible for healthcare investments at Fidelity Growth Partners China from 2012 to 2014. From 2009 to 2012, Dr. Yu served as the Deputy General Manager of the Northeast Office of Shenzhen Capital Group, where he helped found the branch and was responsible for developing investment opportunities in the region. Prior to this, Dr. Yu worked in the Global Healthcare Department of UBS Investment Bank and McKinsey’s New York office. Dr. Yu has also conducted research in bioinformatics and structured drug design at Yale University and Columbia University, respectively.
In 2021, Dr. Yu was rated by 36Kr as China’s TOP20 Investors in Healthcare.
Partner
Shanghai office
+86-21-6162-0600
eric.yu@matrixpartners.com.cn
Bota Bio
Advaccine
SCIVITA MEDCIAL
Triastek
Chemclin
Peijia
Huahui Health
ONE Chip
NovoCodex Bio
InventisBio
Up Clinics.
Genecast
Healthcare
Fidelity Growth Partners China, VP
Northeastern office of Shenzhen Capital Group, Deputy General Manager
UBS Investment Bank
McKinsey
Ph.D. in computational Chemistry, Columbia University
MBA in Tuck School of Business at Dartmouth, Columbia
B.S in chemistry, Peking University